Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

NCT03327727 is registered in ClinicalTrials.gov with Vical as lead sponsor.

NCT NCT03327727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03327727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients
Lead sponsor
Vical
Phase
Phase 2
Overall status
Terminated
Start date
February 20, 2018
Completion date
January 14, 2019
Enrollment
4 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis, invasive pulmonary aspergillosis